VYGR

Peers: ACIU NGNE RGNX ALEC DNLI QURE PRTA TSHA ABOS MGTX

| Held by: VTI IWM VXF IWN VTWO IBB DFAS FESM IWC AVSC

Index	RUT
Market Cap	114.30M
Enterprise Value	30.53M
Income	-107.73M
Sales	34.46M
Book/sh	2.52
Cash/sh	1.89
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	141
IPO	Nov 11, 2015

P/E	-
Forward P/E	-
PEG	-
P/S	3.32
P/B	0.74
P/C	0.98
P/FCF	-
EV/EBITDA	-
EV/Sales	0.89
Quick Ratio	7.51
Current Ratio	7.51
Debt/Eq	0.21
LT Debt/Eq	0.17
Option/Short	Yes / Yes

EPS (ttm)	-1.81
EPS next Y	-1.31
EPS next Q	-0.42
EPS this Y	16.44%
EPS next Y	23.25%
EPS next 5Y	17.58%
EPS past 3/5Y	-19.02% -
Sales past 3/5Y	-0.44% -25.09%
EPS Y/Y TTM	2.07%
Sales Y/Y TTM	-19.07%
EPS Q/Q	28.96%
Sales Q/Q	-39.13%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	17.32% -29.97%

Insider Own	16.27%
Insider Trans	0.00%
Inst Own	57.88%
Inst Trans	1.14%
ROA	-41.45%
ROE	-54.09%
ROIC	-59.83%
Gross Margin	88.91%
Oper. Margin	-340.08%
Profit Margin	-312.63%
SMA20	-5.68%
SMA50	-29.04%
SMA200	-45.90%
Trades

Shs Outstand	61.27M
Shs Float	51.59M
Short Float	7.05%
Short Ratio	5.39
Short Interest	3.64M
52W High	5.48 -66.14%
52W Low	1.67 10.75%
Volatility	6.52% 7.48%
ATR (14)	0.14
RSI (14)	37.23
Beta	1.17
Rel Volume	0.87
Avg Volume	675.25K
Volume	499,283

Perf Week	0.82%
Perf Month	-24.59%
Perf Quarter	-40.73%
Perf Half Y	-55.52%
Perf YTD	-52.80%
Perf Year	-55.41%
Perf 3Y	-72.35%
Perf 5Y	-50.93%
Perf 10Y	-83.81%
Recom	1.09
Target Price	14.89
Prev Close	1.83
Price	1.86
Change %	1.37%

Consensus

Strong Buy

Avg. Price Target

$14.89

Implied Upside

+702.7%

Analysts13incl. previous ratings

Rating Distribution11 Buy · 2 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
Jan 10, 2025	Initiated	CCantor Fitzgerald	Overweight
Dec 02, 2024	Initiated	CCitigroup	Buy	$12	+546.9%
Nov 29, 2024	Resumed	WWedbush	Outperform	$7 → $11	+493.0%
Oct 16, 2024	Initiated	LLeerink Partners	Outperform	$15	+708.6%
Mar 26, 2024	Initiated	GGuggenheim	Buy	$22	+1,086.0%
Mar 19, 2024	Initiated	HH.C. Wainwright	Buy	$30	+1,517.3%
Mar 07, 2024	Initiated	CCitigroup	Buy	$16	+762.5%
Jan 02, 2024	Upgrade	WWells Fargo	Equal Weight → Overweight	$14	+654.7%
May 10, 2023	Initiated	TTruist	Buy	$18	+870.4%
Mar 10, 2023	Initiated	OOppenheimer	Outperform	$14	+654.7%
Oct 07, 2021	Upgrade	RRobert W. Baird	Neutral → Outperform	$6 → $9	+385.2%
Feb 26, 2021	Downgrade	RRobert W. Baird	Outperform → Neutral	$18 → $6	+223.5%
Feb 03, 2021	Downgrade	WWedbush	Outperform → Neutral	$6	+223.5%
Feb 03, 2021	Downgrade	BBTIG Research	Buy → Neutral
Dec 24, 2020	Downgrade	CCantor Fitzgerald	Overweight → Neutral	$15 → $10	+439.1%
Dec 23, 2020	Downgrade	RRaymond James	Outperform → Mkt Perform
Nov 11, 2020	Downgrade	OOppenheimer	Outperform → Perform
Nov 10, 2020	Downgrade	WWells Fargo	Overweight → Equal Weight	$10	+439.1%
Nov 10, 2020	Downgrade	RRaymond James	Strong Buy → Outperform	$28 → $17	+816.4%
Mar 19, 2020	Initiated	TThe Benchmark Company	Buy	$18	+870.4%

Oct-27-26 08:01AM	Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026 (GlobeNewswire)
Oct-21-26 08:01AM	Voyager Announces CEO Succession Plan, Appoints Robin Swartz President (GlobeNewswire) -7.76%
Sep-01-26 08:00AM	Voyager to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-06-26 04:44PM	Voyager Therapeutics: Q2 Earnings Snapshot (Associated Press)
04:01PM	Voyager Reports Second Quarter 2026 Financial and Operating Results (GlobeNewswire)
08:01AM	Loading…
Jul-13-26 08:01AM	Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 (GlobeNewswire) -5.81%
02:00AM	Can Biogen Convince Skeptics That Cutting a Rogue Protein Slows Alzheimer's? (Barrons.com)
Jun-29-26 08:01AM	Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 (GlobeNewswire)
Jun-11-26 04:01PM	Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
Jun-01-26 08:00AM	Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease (GlobeNewswire)
May-13-26 06:01AM	Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026 (GlobeNewswire)
May-07-26 04:40PM	Voyager Therapeutics: Q1 Earnings Snapshot (Associated Press) -5.04%
04:01PM	Voyager Reports First Quarter 2026 Financial and Operating Results (GlobeNewswire)
Apr-27-26 04:31PM	Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's Disease (GlobeNewswire)
Mar-09-26 05:15PM	Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +5.38% +21.65%
04:22PM	Loading…
04:22PM	Voyager Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results (GlobeNewswire)
Mar-05-26 05:30PM	Lineage Cell (LCTX) Reports Break-Even Earnings for Q4 (Zacks)
Mar-02-26 05:03AM	Voyager Therapeutics Touts Tau, Gene Therapy and NeuroShuttle Roadmap, Sees Cash Runway Into 2028 (MarketBeat)
Feb-26-26 09:55AM	Fortrea Holdings Inc. (FTRE) Q4 Earnings and Revenues Lag Estimates (Zacks)
Feb-09-26 08:00AM	Voyager to Present at Upcoming Investor Conferences (GlobeNewswire)
Dec-10-25 02:14PM	Voyager Therapeutics (VYGR): Strong Q3 Prompts Bullish Coverage (Insider Monkey)
Nov-10-25 09:15AM	Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
08:14AM	Voyager Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
08:01AM	Voyager Reports Third Quarter 2025 Financial and Operating Results (GlobeNewswire)
08:01AM	Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia (GlobeNewswire)
Nov-06-25 08:15AM	Moderna (MRNA) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
Oct-09-25 10:19AM	Voyager Therapeutics (VYGR) Soars 11.6%: Is Further Upside Left in the Stock? (Zacks)
Sep-15-25 02:00PM	Voyager Therapeutics Alzheimer's Portfolio And ALPL NeuroShuttle Underscore Platform Momentum: Analyst (Benzinga)
Aug-26-25 07:00AM	Voyager to Present at Upcoming Investor Conferences (GlobeNewswire)
05:30PM	Loading…
Aug-06-25 05:30PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Lags Revenue Estimates (Zacks) -5.29%
04:29PM	Voyager Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Reports Second Quarter 2025 Financial and Operating Results (GlobeNewswire)
Jul-16-25 07:00AM	Voyager Adds Fourth Wholly-Owned Alzheimer's Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach (GlobeNewswire) +6.34%
Jun-10-25 07:00AM	Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference (GlobeNewswire)
Jun-01-25 06:05AM	Oppenheimer Predicts Up to ~550% Jump for These 2 Strong Buy Stocks (TipRanks)
May-15-25 07:00AM	Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication (GlobeNewswire)
May-06-25 05:10PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -6.88%
04:01PM	Voyager Reports First Quarter 2025 Financial and Operating Results (GlobeNewswire)
Apr-28-25 04:30PM	Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting (GlobeNewswire)
Apr-21-25 04:33PM	Voyager Therapeutics Inc (VYGR) Q4 2024 Earnings Call Highlights: Strong Financial Position and ... (GuruFocus.com)
Mar-31-25 07:00AM	Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD 2025 (GlobeNewswire) -7.40%
Mar-20-25 09:00PM	Bragar Eagel & Squire, P.C. Is Investigating Dave, Red Cat, Perpetua, and Voyager and Encourages Investors to Contact the Firm (GlobeNewswire) -5.13%
Mar-12-25 12:02PM	Q4 2024 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 05:10PM	Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates (Zacks)
04:25PM	Voyager Therapeutics: Q4 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results (GlobeNewswire)
Mar-04-25 07:00AM	Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast (GlobeNewswire)
02:11AM	New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimers approach (Pharma Voice)
Mar-03-25 07:00AM	Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer's Disease (GlobeNewswire)
Feb-25-25 07:00AM	Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences (GlobeNewswire)
Feb-12-25 08:01AM	Voyager Therapeutics, Inc. (VYGR): A Cheap Biotech Stock to Invest In Now (Insider Monkey) +5.11%
Feb-11-25 07:00AM	Voyager Provides Update on SOD1 ALS Gene Therapy Program (GlobeNewswire) -20.96%
Feb-06-25 07:00AM	Voyager to Present at Oppenheimer 25th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-30-25 12:00PM	What Makes Voyager Therapeutics (VYGR) a New Buy Stock (Zacks)
Dec-29-24 06:22AM	Voyager Therapeutics, Inc. (VYGR): Is This Gene Therapy Stock a Good Buy Right Now? (Insider Monkey)
Dec-03-24 09:55AM	Wall Street Analysts See a 152.53% Upside in Voyager Therapeutics (VYGR): Can the Stock Really Move This High? (Zacks) -5.19%
Nov-30-24 06:55AM	Wedbush upgrades Voyager to Outperform on pipeline progress (TipRanks)
Nov-20-24 07:00AM	Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer's Disease (GlobeNewswire)
Nov-13-24 08:37AM	Q3 2024 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
02:18AM	Voyager Therapeutics Inc (VYGR) Q3 2024 Earnings Call Highlights: Strong Cash Position and ... (GuruFocus.com)
Nov-12-24 05:20PM	Voyager Therapeutics (VYGR) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:19PM	Voyager Therapeutics: Q3 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Reports Third Quarter 2024 Financial and Operating Results (GlobeNewswire)
Nov-06-24 07:00AM	Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences (GlobeNewswire) +9.47%
Nov-05-24 07:00AM	Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast (GlobeNewswire)
Oct-28-24 10:01AM	Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Can the Stock Move Higher? (Zacks)
Oct-07-24 05:16AM	Strength Seen in Voyager Therapeutics (VYGR): Can Its 17.5% Jump Turn into More Strength? (Zacks)
Sep-16-24 07:00AM	Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected (GlobeNewswire)
Sep-05-24 08:00AM	Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14 (GlobeNewswire)
Aug-29-24 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:00AM	Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences (GlobeNewswire)
Aug-07-24 07:00AM	Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase (GlobeNewswire) -14.04%
Aug-06-24 05:15PM	Voyager Therapeutics (VYGR) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:11PM	Voyager Therapeutics: Q2 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results (GlobeNewswire)
Jul-30-24 07:00AM	Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast (GlobeNewswire)
Jul-23-24 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jul-09-24 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-24 04:01PM	Voyager Therapeutics to Present at Multiple Virtual Investor Conferences (GlobeNewswire)
07:00AM	Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer (GlobeNewswire)
May-16-24 07:00AM	Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer's Disease (GlobeNewswire)
May-14-24 08:16AM	Q1 2024 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
06:27AM	Wedbush Adjusts Voyager Therapeutics' PT to $8 From $10, Keeps Neutral Rating (MT Newswires)
03:03AM	Voyager Therapeutics Inc (VYGR) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 08:56PM	VYGR Stock Earnings: Voyager Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
05:10PM	Voyager Therapeutics (VYGR) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
04:09PM	Voyager Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
04:01PM	Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results (GlobeNewswire)
May-08-24 06:00AM	Voyager Therapeutics Presents Data for Second-Generation, TRACER-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting (GlobeNewswire)
May-06-24 07:00AM	Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast (GlobeNewswire)
Apr-22-24 04:30PM	Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting (GlobeNewswire)
Apr-16-24 07:00AM	Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment (GlobeNewswire)
Mar-30-24 03:00AM	Buy Voyager Stock, Analyst Says. The Little Biotech Could Have Big Breakthroughs. (Barrons.com)
Mar-26-24 04:01PM	Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.21%
Mar-13-24 07:00AM	Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer (GlobeNewswire)
Mar-09-24 01:09PM	12 Most Undervalued Biotech Stocks To Buy According To Hedge Funds (Insider Monkey)
Feb-29-24 11:09AM	Q4 2023 Voyager Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -7.25%
09:54AM	Voyager Therapeutics, Inc. (NASDAQ:VYGR) Q4 2023 Earnings Call Transcript (Insider Monkey)
Feb-28-24 04:41PM	Voyager Therapeutics Inc (VYGR) Announces Strong Year-End Financials with Significant Cash Position (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jorgensen Nathan D.	Former Officer	May 15 '26	Proposed Sale	3.88	25,000	96,941		May 15 04:07 PM
Jorgensen Nathan D.	Former Officer	May 15 '26	Proposed Sale	4.24	9,406	39,881		May 15 10:34 AM
Sandrock Alfred	President and CEO	Apr 02 '26	Sale	3.87	11,511	44,548	472,549	Apr 03 05:55 PM
Sandrock Alfred	Officer	Apr 02 '26	Proposed Sale	3.87	11,511	44,597		Apr 02 03:53 PM
Swartz Robin	COO & CBO	Feb 24 '26	Sale	3.77	6,458	24,347	199,738	Feb 26 09:48 AM
Sandrock Alfred	President and CEO	Feb 24 '26	Sale	3.79	14,197	53,807	484,060	Feb 26 09:47 AM
Jorgensen Nathan D.	Chief Financial Officer	Feb 24 '26	Sale	3.77	4,668	17,598	151,416	Feb 26 09:46 AM
Carter Todd Alfred	Chief Scientific Officer	Feb 24 '26	Sale	3.76	4,174	15,694	145,718	Feb 26 09:44 AM
Carter Todd Alfred	Officer	Feb 24 '26	Proposed Sale	3.76	4,174	15,711		Feb 24 05:17 PM
Jorgensen Nathan D.	Officer	Feb 24 '26	Proposed Sale	3.77	4,668	17,588		Feb 24 05:16 PM
Swartz Robin	Officer	Feb 24 '26	Proposed Sale	3.77	6,458	24,335		Feb 24 05:10 PM
Sandrock Alfred	Officer	Feb 24 '26	Proposed Sale	3.79	14,197	53,852		Feb 24 05:09 PM
Swartz Robin	COO & CBO	Feb 18 '26	Sale	3.44	3,882	13,354	206,196	Feb 20 04:04 PM
Carter Todd Alfred	Chief Scientific Officer	Feb 18 '26	Sale	3.44	3,301	11,355	149,892	Feb 20 04:03 PM
Sandrock Alfred	President and CEO	Feb 18 '26	Sale	3.41	11,732	40,006	498,257	Feb 20 04:01 PM
Sandrock Alfred	Officer	Feb 18 '26	Proposed Sale	3.41	11,732	40,039		Feb 18 04:15 PM
Carter Todd Alfred	Officer	Feb 18 '26	Proposed Sale	3.44	3,301	11,346		Feb 18 03:50 PM
Swartz Robin	Officer	Feb 18 '26	Proposed Sale	3.44	3,882	13,349		Feb 18 03:45 PM
Swartz Robin	COO & CBO	Feb 10 '26	Sale	3.85	4,569	17,591	210,078	Feb 11 04:32 PM
Sandrock Alfred	President and CEO	Feb 10 '26	Sale	3.78	12,192	46,086	509,989	Feb 11 04:30 PM
Carter Todd Alfred	Chief Scientific Officer	Feb 10 '26	Sale	3.85	3,525	13,571	153,193	Feb 11 04:30 PM
Sandrock Alfred	Officer	Feb 10 '26	Proposed Sale	3.78	12,192	46,093		Feb 10 04:23 PM
Swartz Robin	Officer	Feb 10 '26	Proposed Sale	3.85	4,569	17,599		Feb 10 03:17 PM
Carter Todd Alfred	Officer	Feb 10 '26	Proposed Sale	3.84	3,525	13,553		Feb 10 03:11 PM

Voyager Therapeutics, Inc. is a clinical-stage gene therapy company, which engages in the development of treatments for severe neurological diseases. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guang Ping Gao, Mark A. Kay, Krystof Bankiewicz, and Phillip Zamore in June 2013 and is headquartered in Lexington, MA.

Ph.D.Dr. Krystof Bankiewicz M.D.

Ph.D.Dr. Mark A. Kay M.D.

Principal Accounting OfficerMs. Amy Quinlan

Chief Scientific OfficerMr. Todd Carter Ph.D.

Chief Corporate Affairs Officer & Chief of Staff to the CEOMs. Trista Morrison

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Voyager Therapeutics Inc

Upgrade your Finviz experience